Stepping Into the Race to Detect Fetal Cells in Maternal Blood
Executive Summary
Many companies have tried and failed to develop tools that could detect fetal cells in maternal blood. Their aim would be to detect pre-natal abnormalities more accurately and earlier than existing tests and to replace invasive methods, such as amniocentesis. Roche Diagnostics started a program in this field six years ago and found several markers distinguishing fetal from maternal cells in blood. But its priorities shifted and recently it licensed the technology to Vysis, which has been doing chromosomal analysis of fetal cells gleaned from amniocentesisYou may also be interested in...
Vysis Preps For Prime Time
Tiny Vysis scored big this spring, winning the backing of two major therapeutic and diagnostic companies for its products. But is its core technology ready for prime time? Vysis sees an opportunity to expand use of its FISH diagnostics technology beyond niche applications in the clinical market. But skeptics say the technology is too complex and expensive for routine clinical use.
AstraZeneca's Risky Lynparza Endpoint In Pancreatic Cancer Goes Before Advisory Cmte.
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports